Cyteir Therapeutics, Inc. Common Stock
CYT
CYT was delisted on the 15th of March, 2024.
39 hedge funds and large institutions have $41.7M invested in Cyteir Therapeutics, Inc. Common Stock in 2023 Q2 according to their latest regulatory filings, with 12 funds opening new positions, 7 increasing their positions, 8 reducing their positions, and 5 closing their positions.
140% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 5
22% more funds holding
Funds holding: 32 → 39 (+7)
13% less repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 8
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
70% less capital invested
Capital invested by funds: $137M → $41.7M (-$95.1M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AFM
Anson Funds Management
Dallas,
Texas
|
+$2.41M |
| 2 |
WSL
Western Standard LLC
Los Angeles,
California
|
+$1.1M |
| 3 |
NM
Newtyn Management
New York
|
+$848K |
| 4 |
AI
Acuitas Investments
Seattle,
Washington
|
+$689K |
| 5 |
VAM
Vazirani Asset Management
New York
|
+$327K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
APM
Avidity Partners Management
Dallas,
Texas
|
-$3.21M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$2.98M |
| 3 |
NHAS
Novo Holdings A/S
Hellerup,
Denmark
|
-$582K |
| 4 |
Morgan Stanley
New York
|
-$250K |
| 5 |
CCM
CAAS Capital Management
New York
|
-$243K |
CYT Hedge Fund Activity: Q2 2023 in Review
39 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Cyteir Therapeutics, Inc. Common Stock (CYT) for Q2 2023, worth a combined $41.7M — down 70% from $137M a quarter earlier.
Buyers outnumbered sellers: 12 funds opened new CYT positions and 5 closed out — a net gain of 7 holders — while 7 added to existing stakes and 8 trimmed.
The largest buyer was Anson Funds Management, opening a new position worth an estimated $2.41M. The largest seller was Avidity Partners Management, exiting entirely with an estimated $3.21M sold.
- 39 institutional investors held Cyteir Therapeutics, Inc. Common Stock (CYT) as of Q2 2023, up from 32 in Q1 2023.
- Funds reported $41.7M of Cyteir Therapeutics, Inc. Common Stock stock for Q2 2023, down 70% quarter-over-quarter.
- 12 funds opened new Cyteir Therapeutics, Inc. Common Stock positions in Q2 2023 and 5 closed out, a net change of +7 holders.
- The largest Cyteir Therapeutics, Inc. Common Stock buyer in Q2 2023 was Anson Funds Management, an estimated $2.41M added.
- The largest Cyteir Therapeutics, Inc. Common Stock seller in Q2 2023 was Avidity Partners Management, an estimated $3.21M sold.
Based on aggregated 13F filings for Q2 2023.